Viking Therapeutics will showcase data on its lead obesity candidate, VK2735, during two poster sessions at the ObesityWeek 2026 conference held from November 14–17.
The announcement covers two poster presentations at ObesityWeek (November 14-17, 2026) showing baseline characteristics and Phase 2 VENTURE data, but contains no new efficacy figures, trial results, or guidance. Posters of already-conducted analyses are routine scientific communication and are unlikely to move the stock materially.
Viking Therapeutics announced two upcoming poster presentations at the ObesityWeek 2026 conference in Washington, D.C. The sessions, scheduled for November 14 and 15, will detail baseline characteristics from the Phase 3 VANQUISH-2 trial and analyze cardiometabolic impacts from the Phase 2 VENTURE study of its dual GLP-1/GIP receptor agonist, VK2735.
No. The posters present baseline characteristics from the Phase 3 VANQUISH-2 trial and an analysis of the already-reported Phase 2 VENTURE study; no new efficacy or safety numbers are included in the announcement.
At ObesityWeek in Washington, D.C., on November 14 and November 15, 2026.